Trial Profile
An Open-label, Non-randomized Phase 2 Study of Ofatumomab (O) in Combination With ICE (Ifosfamide, Carboplatin, Etoposide)-Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Ofatumumab (Primary) ; Carboplatin; Etoposide; Ifosfamide
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 21 Mar 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 15 Apr 2015 New trial record